BiPER Therapeutics Raises €800K Funding for Cancer Treatment BiPER Therapeutics has now secured €800k in bridge funding to help develop its novel BiP inhibitor, BPR001-615, for the treatment of gastrointestinal malignancies. The funding raised will assist in refining BPR001-615’s pathology and regulatory preclinical study and advance toward first-in-human trials. Visit: https://nextdigitalhealth.com/funding-news/biper-therapeutics-raises-e800k-funding-for-cancer-treatment/ #healthcare #funding #healthcarefunding #Bipertherapetuics #cancertreatment